SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 206 CNY | +0.58% |
|
+7.34% | +58.17% |
| Sales 2024 * | 2.12B 292M | Sales 2025 * | 2.68B 370M | Capitalization | 35.93B 4.96B |
|---|---|---|---|---|---|
| Net income 2024 * | 449M 62.01M | Net income 2025 * | 669M 92.39M | EV / Sales 2024 * | 17 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 13.4 x |
| P/E ratio 2024 * |
80.1
x | P/E ratio 2025 * |
53.7
x | Employees | 1,995 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 65.96% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.58% | ||
| 1 week | +7.34% | ||
| 1 month | +11.09% | ||
| 3 months | +90.86% | ||
| 6 months | +87.86% | ||
| Current year | +58.17% |
1 week
189.27
214.36
1 month
182.27214.36
Current year
92.86214.36
1 year
80.17214.36
3 years
40.05214.36
5 years
23.76214.36
10 years
3.16214.36
| Managers | Title | Age | Since |
|---|---|---|---|
E Gao
CEO | Chief Executive Officer | 50 | 00-07-04 |
| 37 | - | ||
Ya Nan Cheng
DFI | Director of Finance/CFO | 50 | 02-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xiao Yan Kong
BRD | Director/Board Member | 51 | Jan. 04 |
Ji Dong Liu
CHM | Chairman | 67 | 00-07-04 |
E Gao
CEO | Chief Executive Officer | 50 | 00-07-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.43% | 12 M€ | -16.71% | - | |
| 0.00% | 34 M€ | +3.86% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 206 | +0.58% | 3,020,564 |
| 24-05-30 | 204.8 | +0.79% | 4,311,073 |
| 24-05-29 | 203.2 | +3.18% | 3,844,599 |
| 24-05-28 | 196.9 | +1.94% | 3,459,118 |
| 24-05-27 | 193.2 | +0.67% | 2,003,467 |
End-of-day quote Shenzhen S.E., May 30, 2024
More quotes
SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Companyâs main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
206
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +58.17% | 4.96B | |
| +15.54% | 78.51B | |
| +12.05% | 9B | |
| -14.94% | 4.84B | |
| -.--% | 3.72B | |
| +21.94% | 2.48B | |
| -26.63% | 2.19B | |
| +16.75% | 2.12B | |
| -37.97% | 1.94B | |
| -0.50% | 1.64B |
- Stock Market
- Equities
- 300573 Stock
